Premium
Mammalian target of rapamycin as a therapeutic target in osteoporosis
Author(s) -
Shen Gengyang,
Ren Hui,
Qiu Ting,
Zhang Zhida,
Zhao Wenhua,
Yu Xiang,
Huang Jinjing,
Tang Jingjing,
Liang De,
Yao Zhensong,
Yang Zhidong,
Jiang Xiaobing
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26161
Subject(s) - pi3k/akt/mtor pathway , osteoporosis , homeostasis , bone resorption , adipogenesis , microbiology and biotechnology , bone marrow , bone remodeling , pathogenesis , mesenchymal stem cell , signal transduction , biology , endocrinology , immunology
The mechanistic target of rapamycin (mTOR) plays a key role in sensing and integrating large amounts of environmental cues to regulate organismal growth, homeostasis, and many major cellular processes. Recently, mounting evidences highlight its roles in regulating bone homeostasis, which sheds light on the pathogenesis of osteoporosis. The activation/inhibition of mTOR signaling is reported to positively/negatively regulate bone marrow mesenchymal stem cells (BMSCs)/osteoblasts‐mediated bone formation, adipogenic differentiation, osteocytes homeostasis, and osteoclasts‐mediated bone resorption, which result in the changes of bone homeostasis, thereby resulting in or protect against osteoporosis. Given the likely importance of mTOR signaling in the pathogenesis of osteoporosis, here we discuss the detailed mechanisms in mTOR machinery and its association with osteoporosis therapy.